PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology provider for modern clinical trials, achieved an impressive 75% adoption of its Total Consent solution deployed in elderly ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology provider for modern clinical trials, announces new intelligent automation technology applied across its clinical trials ...

Over 70% of potential research participants live >2 hours away from a research site, & patient drop-out rates can reach 30% depending on the therapeutic area. The Solution: Medable eConsent Why? 1.

Medable Inc., the leading technology platform for clinical trials, today announced Medable Studio, an all-in-one application for configuring, translating, validating, and launching eCOA Plus (eCOA, ...

Medable Inc., a leading provider of clinical development technology, announced that its eConsent and eCOA solutions have been approved for use in two clinical studies in eight countries outside of the ...

eConsent can reduce barriers and improve the clinical trial experience for patients and sites. We sat down with Dr Caroline Forkin, senior director medical affairs of FIRECREST, ICON, to discuss this ...

As researchers and clinicians develop new medical products, they turn to clinical trials in humans to answer questions related to product safety, need, and efficacy. It is crucial that trial ...

Medable landed GlaxoSmithKline with a four-year deal to use the trial software firm's platform for decentralized clinical trials and to recruit more diverse trial patient populations. (ajijchan/Getty ...

Currently, according to Tufts researchers, clinical trials in a variety of therapeutic areas experience patient dropout rates close to 20%, with the consent process being the number one factor ...

Medable Studio for eCOA now available; two top-10 pharma company early adopters PALO ALTO, Calif., August 14, 2024--(BUSINESS WIRE)--Medable Inc., the leading technology platform for clinical trials, ...